Prevalence and risk of DOACs inappropriate dosing in atrial fibrillation. An analysis of the Swiss-AF and BEAT-AF registries

Back

ESC Premium Access

Prevalence and risk of DOACs inappropriate dosing in atrial fibrillation. An analysis of the Swiss-AF and BEAT-AF registries

Session: Poster Session 2 - Drug treatment for atrial fibrillation

Topic: Oral Anticoagulation

Speaker: Doctor G. Montrasio (London, GB)

Event: ESC Congress 2019

Congress Presentation

About the speaker

Doctor Giulia Montrasio

Barts Heart Centre, London (United Kingdom of Great Britain & Northern Ireland)

0 follower

9 more presentations in this session

Heparin and low-molecular-weight heparin switch associated with an increase in bleeding complications in patients on apixaban undergoing catheter ablation: The AMPER ABLATION study

Speaker: Doctor W. Amara (Le Raincy-Montfermeil, FR)

Access

Abstract

Amiodarone treatment duration and reasons for permanent drug discontinuation in patients with atrial fibrillation

Speaker: Doctor M. Mihajlovic (Belgrade, RS)

Access

Abstract

Slides

Use of direct thrombin inhibitor on the day of atrial fibrillation ablation decreases incidence of silent cerebral ischemia detected by magnetic resonance imaging

Speaker: Associate Professor M. Harada (Toyoake, JP)

Access

Abstract

Comparison of efficacy of different anticoagulation strategies used during pulmonary vein isolation in left atrial blood samples

Speaker: Doctor O. Hajas (Debrecen, HU)

Access

Abstract

Slides

Efficacy and safety of dronedarone after recent cardioversion in patients with atrial fibrillation/flutter: a post-hoc analysis of the EURIDIS/ADONIS trials

Speaker: Professor H. Crijns (Maastricht, NL)

Access

Abstract

Slides

Access the full session

Poster Session 2 - Drug treatment for atrial fibrillation

Speakers: Doctor G. Montrasio, Doctor W. Amara, Doctor M. Mihajlovic, Associate Professor M. Harada, Doctor O. Hajas...

Access

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

Prevalence and risk of DOACs inappropriate dosing in atrial fibrillation. An analysis of the Swiss-AF and BEAT-AF registries

About the speaker

Doctor Giulia Montrasio

9 more presentations in this session

Heparin and low-molecular-weight heparin switch associated with an increase in bleeding complications in patients on apixaban undergoing catheter ablation: The AMPER ABLATION study

Amiodarone treatment duration and reasons for permanent drug discontinuation in patients with atrial fibrillation

Use of direct thrombin inhibitor on the day of atrial fibrillation ablation decreases incidence of silent cerebral ischemia detected by magnetic resonance imaging

Comparison of efficacy of different anticoagulation strategies used during pulmonary vein isolation in left atrial blood samples

Efficacy and safety of dronedarone after recent cardioversion in patients with atrial fibrillation/flutter: a post-hoc analysis of the EURIDIS/ADONIS trials

Access the full session

Poster Session 2 - Drug treatment for atrial fibrillation

About the event

ESC Congress 2019

ESC 365 is supported by